What is the 13F Pro Quality Score for ABOS?

13F Pro ranks Acumen Pharmaceuticals, Inc. (ABOS) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ABOS's current score at https://13fpro.ai/research/ABOS (free sign-up required for the full ranking).

Where does 13F Pro source ABOS data?

All Acumen Pharmaceuticals, Inc. fundamentals and ownership data come directly from SEC EDGAR. Acumen Pharmaceuticals, Inc. files with the SEC under CIK 1576885. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ABOS in?

Acumen Pharmaceuticals, Inc. (ABOS) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ABOS research updated on 13F Pro?

ABOS's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Acumen Pharmaceuticals, Inc.(ABOS)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1576885 ABOS stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

ABOS Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Acumen Pharmaceuticals, Inc. (ABOS), a Healthcare sector company. ABOS is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), Acumen Pharmaceuticals, Inc. reports net income of $-20.7M, free cash flow of $-24.1M. Top institutional holders of ABOS by reported 13-F value include RA CAPITAL MANAGEMENT, L.P., Sands Capital Ventures,, Alyeska Investment Group, L.P., based on the most recent SEC filings. ABOS trades on the Nasdaq exchange and files with the SEC under CIK 1576885. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ABOS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Acumen Pharmaceuticals, Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-20.7M

Free Cash Flow

Q1 2026

$-24.1M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

-95.4% YoY

$-102.3MFY 2024

FY19 —FY20 $-7.3MFY23 $-52.4MFY24 $-102.3M

Operating Income

-86.5% YoY

$-114.0MFY 2024

FY19 —FY20 $-7.9MFY23 $-61.1MFY24 $-114.0M

EPS (Diluted)

-58.3% YoY

$-1.71FY 2024

FY19 —FY20 —FY23 $-1.08FY24 $-1.71

Total Assets

-22.9% YoY

$239.0MFY 2024

FY19 —FY20 $44.4MFY23 $310.1MFY24 $239.0M

Total Debt

-1.6% YoY

$29.4MFY 2024

FY19 —FY20 —FY23 $29.9MFY24 $29.4M

Op. Cash Flow

-100.2% YoY

$-86.2MFY 2024

FY19 —FY20 $-7.5MFY23 $-43.1MFY24 $-86.2M

Metric	FY 2024	FY 2023	FY 2020	FY 2019
Net Income	$-102.3M -95.4%	$-52.4M -615.0%	$-7.3M	—
Operating Income	$-114.0M -86.5%	$-61.1M -672.7%	$-7.9M	—
EPS (Diluted)	$-1.71 -58.3%	$-1.08	—	—
Total Assets	$239.0M -22.9%	$310.1M +598.0%	$44.4M	—
Total Debt	$29.4M -1.6%	$29.9M	—	—
Operating Cash Flow	$-86.2M -100.2%	$-43.1M -478.0%	$-7.5M	—

AI Insight: ABOS Financial Trends

Equity has collapsed from $244M to $87M in seven quarters as cash burn continues with zero revenue generated.

• Equity eroded 64% from $244M in Q2 2024 to $87M in Q1 2026, driven by sustained net losses every quarter.

• Operating losses ranged from -$21M to -$42M per quarter; Q2 2025 was the worst at -$42M, with Q1 2026 improving slightly to -$21M.

• Total debt remained essentially flat at $29–$31M across all eight quarters, indicating no significant incremental debt financing.

⚠ Equity of $87M against quarterly cash burn of ~$19–$34M implies a runway of roughly 2–4 quarters without new financing.

⚠ No revenue has appeared in any reported quarter — any catalyst triggering a revenue line would be a critical inflection point.

⚠ Operating cash outflow ticked back up to -$24M in Q1 2026 after improving to -$19M in Q4 2025 — burn reduction not yet sustained.

AI Insight: ABOS Ratio Trends

ABOS return metrics have deteriorated sharply since Q2 2024, with ROE deepening from -33.7% to as low as -142.8% in Q4 2025, signaling accelerating cash burn.

• ROE worsened from -33.7% in Q2 2024 to -142.8% in Q4 2025, a ~109pp deterioration over six quarters.

• ROA fell from -28.4% in Q2 2024 to -95.3% in Q2 2025, reflecting rapid asset base erosion relative to losses.

• D/E ratio climbed steadily from 0.12 in Q2 2024 to 0.44 in Q4 2025, indicating rising leverage as the company funds operations with debt.

• Q1 2026 shows modest sequential improvement: ROE -94.8%, ROA -62.1%, ROIC -71.4%, and D/E easing to 0.35 from Q4 2025 peaks.

⚠ D/E reached 0.44 in Q4 2025 — more than 3.5x the Q2 2024 level; continued debt accumulation could pressure the balance sheet.

⚠ Whether Q1 2026's partial metric recovery (-94.8% ROE vs. -142.8%) marks a genuine inflection or a one-quarter reprieve warrants close monitoring.

⚠ ROIC hit -99.2% in Q4 2025, near total destruction of invested capital returns; TTM ROIC of -96.7% confirms the trend is not just seasonal.

Get alerted when ABOS's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Acumen Pharmaceuticals, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ABOS

RA CAPITAL MANAGEMENT, L.P.
$49.5M20,992,669 sh
Sands Capital Ventures, LLC
$8.8M3,720,105 sh
Alyeska Investment Group, L.P.
$5.8M2,454,754 sh
FRANKLIN RESOURCES INC
$5.4M2,305,096 sh
ADAR1 Capital Management, LLC
$5.1M2,156,334 sh
Knollwood Investment Advisory, LLC
$3.8M1,628,510 sh
VANGUARD CAPITAL MANAGEMENT LLC
$3.6M1,506,277 sh
FMR LLC
$2.7M1,157,346 sh
Ikarian Capital, LLC
$2.5M1,053,797 sh
Hudson Bay Capital Management LP
$2.3M968,940 sh

Fund	Value	Shares
RA CAPITAL MANAGEMENT, L.P.	$49.5M	20,992,669
Sands Capital Ventures, LLC	$8.8M	3,720,105
Alyeska Investment Group, L.P.	$5.8M	2,454,754
FRANKLIN RESOURCES INC	$5.4M	2,305,096
ADAR1 Capital Management, LLC	$5.1M	2,156,334
Knollwood Investment Advisory, LLC	$3.8M	1,628,510
VANGUARD CAPITAL MANAGEMENT LLC	$3.6M	1,506,277
FMR LLC	$2.7M	1,157,346
Ikarian Capital, LLC	$2.5M	1,053,797
Hudson Bay Capital Management LP	$2.3M	968,940

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

ABT

ABBOTT LABORATORIES

Put ABOS on your watchlist

Track score changes the day Acumen Pharmaceuticals, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ABOS a good stock to buy?

13F Pro's AI-powered analysis of Acumen Pharmaceuticals, Inc. (ABOS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ABOS are available on the ABOS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ABOS?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ABOS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Acumen Pharmaceuticals, Inc.'s investment landscape.